Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 18, Issue 6, Pages 461-467Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2018.1476140
Keywords
Agitation; Alzheimer's disease; atypical antipsychotics; dementia; psychosis
Categories
Ask authors/readers for more resources
Introduction: Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, stroke, accelerated cognitive decline and mortality).Areas covered: This review outlines the current guidance on antipsychotic usage and the evidence of their continued usage against a backdrop of emerging pharmacological treatments and an increasing emphasis on the importance of non-pharmacological interventions.Expert commentary: The current justification for antipsychotic use in the context of the changing landscape of prescribing and provide a view on the most promising alternative candidates to this class of drug are appraised.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available